Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression
- PMID: 23535824
- PMCID: PMC3658165
- DOI: 10.1093/hmg/ddt086
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression
Erratum in
- Hum Mol Genet. 2013 Oct 15;22(20):4239. Russel, Roslin [corrected to Russell, Roslin]
Abstract
Associations between single nucleotide polymorphisms (SNPs) at 5p15 and multiple cancer types have been reported. We have previously shown evidence for a strong association between prostate cancer (PrCa) risk and rs2242652 at 5p15, intronic in the telomerase reverse transcriptase (TERT) gene that encodes TERT. To comprehensively evaluate the association between genetic variation across this region and PrCa, we performed a fine-mapping analysis by genotyping 134 SNPs using a custom Illumina iSelect array or Sequenom MassArray iPlex, followed by imputation of 1094 SNPs in 22 301 PrCa cases and 22 320 controls in The PRACTICAL consortium. Multiple stepwise logistic regression analysis identified four signals in the promoter or intronic regions of TERT that independently associated with PrCa risk. Gene expression analysis of normal prostate tissue showed evidence that SNPs within one of these regions also associated with TERT expression, providing a potential mechanism for predisposition to disease.
Figures
Comment in
-
Prostate cancer: Turning the COGS--23 new susceptibility loci identified.Nat Rev Urol. 2013 May;10(5):252. doi: 10.1038/nrurol.2013.81. Epub 2013 Apr 16. Nat Rev Urol. 2013. PMID: 23588404 No abstract available.
References
-
- Martinez-Delgado B., Yanowsky K., Inglada-Perez L., de la H.M., Caldes T., Vega A., Blanco A., Martin T., Gonzalez-Sarmiento R., Blasco M., et al. Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases. J. Med. Genet. 2012;49:341–344. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- C5047/A7357/CRUK_/Cancer Research UK/United Kingdom
- 16565/CRUK_/Cancer Research UK/United Kingdom
- G1000143/MRC_/Medical Research Council/United Kingdom
- C5047/A10692/CRUK_/Cancer Research UK/United Kingdom
- C5047/A3354/CRUK_/Cancer Research UK/United Kingdom
- P30 CA076292/CA/NCI NIH HHS/United States
- 14136/CRUK_/Cancer Research UK/United Kingdom
- G0401527/MRC_/Medical Research Council/United Kingdom
- 15007/CRUK_/Cancer Research UK/United Kingdom
- 10119/CRUK_/Cancer Research UK/United Kingdom
- 10118/CRUK_/Cancer Research UK/United Kingdom
- C1287/A10118/CRUK_/Cancer Research UK/United Kingdom
- G0900871/MRC_/Medical Research Council/United Kingdom
- C16913/A6135/CRUK_/Cancer Research UK/United Kingdom
- R01 CA092447/CA/NCI NIH HHS/United States
- 11022/CRUK_/Cancer Research UK/United Kingdom
- 1 U19 CA 148537-01/CA/NCI NIH HHS/United States
- 16561/CRUK_/Cancer Research UK/United Kingdom
- 10124/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
